{"id":554786,"date":"2021-07-27T18:32:02","date_gmt":"2021-07-27T18:32:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=554786"},"modified":"2021-07-27T18:32:02","modified_gmt":"2021-07-27T18:32:02","slug":"lag3next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lag3next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight_554786.html","title":{"rendered":"LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1627384331.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1627384331.jpeg\" alt=\"LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>LAG-3-Next Generation Immunotherapy Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/lag-3-next-generation-immunotherapy-competitive-landscape?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>LAG-3-Next Generation Immunotherapy Market<\/strong><\/a> report also offers comprehensive insights into <strong>LAG-3-Next Generation Immunotherapy market size<\/strong>, trends, emerging therapies, technological innovations, market barriers, market drivers, ongoing <strong>LAG-3-Next Generation Immunotherapy<\/strong> clinical trials, key pharmaceutical companies, collaboration in the space, and actively pushing the growth of <strong>LAG-3-Next Generation Immunotherapy<\/strong> market size forward in the 7MM [US, EU5(France, Germany, the United Kingdom, Spain, and Italy) and Japan].<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key facts of the <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/lag-3-next-generation-immunotherapy-competitive-landscape?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>LAG-3-Next Generation Immunotherapy Market Report<\/strong><\/a><strong> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>According to Delveinsight, the market is anticipated to show positive growth due to the launch of upcoming therapies in the LAG-3 Next Generationtarget during the forecast period 2022&ndash;2035. Moreover, the US will occupy the maximum market share in the overall market size in 2035.<\/li>\n<li>According to Delveinsight&#8217;s analysis, Among all LAG-3 Immunotherapy target indications, NSCLC will occupy a significant market share of 98.81% by 2035.&nbsp;<\/li>\n<li>The total LAG-3 Market Size by indications is expected to be USD 3,421 Million by 2035.<\/li>\n<li>According to Delveinsight&#8217;s analysis, the market is expected to show positive growth due to the launch of potential upcoming therapies in the LAG-3 target during the forecast period (2022&ndash;2035).<\/li>\n<li>Currently, numerous trials are undergoing different indications for the LAG-3 target. Some of the major indications anticipated to show a better outcome by the launch of novel drugs include Breast Cancer, NSCLC, Gastric, Gastroesophageal Junction Cancer, Melanoma, Colorectal Cancer, Head and Neck Cncer, Multiple Myeloma.<\/li>\n<li>The emerging trend in LAG3 Next-generation Immunotherapies with continuous headway movement along with new emerging technologies for the development of targeted therapies augurs the hopes for better therapeutic alternatives.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lag-3-next-generation-immunotherapy-competitive-landscape?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/lag-3-next-generation-immunotherapy-competitive-landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/9d141675e711c7e98f039647bb8532c1.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Some of <\/strong><strong>LAG-3-Next Generation Immunotherapy Companies<\/strong><strong> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>MacroGenics<\/li>\n<li>Novartis<\/li>\n<li>Bristol-Myers Squibb<\/li>\n<li>Merck<\/li>\n<li>Immutep<\/li>\n<li>Regeneron<\/li>\n<li>Xencor<\/li>\n<li>Incyte Biosciences<\/li>\n<li>Agenus<\/li>\n<li>F-star Therapeutics<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cancer immunotherapy<\/strong> and tumor microenvironment have been at the forefront of research over the past decades. Targeting immune checkpoints, especially programmed death 1 (PD-1)\/programmed death-ligand 1 (PD-L1), has made a breakthrough in treating advanced malignancies. However, the low response rate brings a daunting challenge, changing the focus to dig deeply into the tumor microenvironment for alternative therapeutic targets. Strikingly, the inhibitory immune checkpoint Lymphocyte Activation Gene-3 (LAG-3) holds considerable potential.<\/p>\n<p style=\"text-align: justify;\"><strong>LAG-3<\/strong> suppresses T-cells activation and cytokine secretion, thereby ensuring immune homeostasis. It exerts differential inhibitory impacts on various types of lymphocytes and shows a remarkable synergy with PD-1 to inhibit immune responses. Targeting LAG-3 immunotherapy is moving forward in active clinical trials, and combination immunotherapy of anti-LAG-3 and anti-PD-1 has shown exciting efficacy in fighting PD-1 resistance.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/lag-3-next-generation-immunotherapy-competitive-landscape?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>LAG-3-Next Generation Immunotherapy Drugs<\/strong><\/a><strong> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>MGD013<\/li>\n<li>LAG525<\/li>\n<li>Relatlimab<\/li>\n<li>MK-4280<\/li>\n<li>Eftilagimod Alpha<\/li>\n<li>INCAGN2385<\/li>\n<li>FS118<\/li>\n<li>REGN3767<\/li>\n<li>XmAb22841<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the <\/strong><strong>LAG-3-Next Generation Immunotherapy Market<\/strong><strong> Insight Report&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Geography Covered:<\/strong> The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>Study Period:<\/strong> 3-year historical and 10-year forecasted analysis (2020-2035).<\/p>\n<p style=\"text-align: justify;\"><strong>Key LAG-3-Next Generation Immunotherapy Companies:<\/strong> MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, Regeneron, Xencor, and others.<\/p>\n<p style=\"text-align: justify;\"><strong>Case Studies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>KOL&#8217;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Analyst&#8217;s View<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the report offerings @<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/onychomycosis-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong> LAG-3-Next Generation Immunotherapy Market Outlook<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Delveinsight :&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight Business Research is a leading Market Research and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.<\/p>\n<p style=\"text-align: justify;\">Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform <strong>PharmDelve<\/strong>.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=lag3next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/lag-3-next-generation-immunotherapy-competitive-landscape\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/lag-3-next-generation-immunotherapy-competitive-landscape<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/lag-3-next-generation-immunotherapy-competitive-landscape\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=lag3next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LAG-3-Next Generation Immunotherapy Market DelveInsight&#8217;s LAG-3-Next Generation Immunotherapy Market report also offers comprehensive insights into LAG-3-Next Generation Immunotherapy market size, trends, emerging therapies, technological innovations, market barriers, market drivers, ongoing LAG-3-Next Generation Immunotherapy clinical trials, key pharmaceutical companies, collaboration in &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/lag3next-generation-immunotherapy-market-size-is-projected-to-reach-usd-7009-million-by-2035-estimates-delveinsight_554786.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-554786","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/554786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=554786"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/554786\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=554786"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=554786"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=554786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}